UY33818A - Nueva composicion farmaceutica - Google Patents

Nueva composicion farmaceutica

Info

Publication number
UY33818A
UY33818A UY0001033818A UY33818A UY33818A UY 33818 A UY33818 A UY 33818A UY 0001033818 A UY0001033818 A UY 0001033818A UY 33818 A UY33818 A UY 33818A UY 33818 A UY33818 A UY 33818A
Authority
UY
Uruguay
Prior art keywords
new pharmaceutical
pharmaceutical composition
dimethyl
trioxo
pyrido
Prior art date
Application number
UY0001033818A
Other languages
English (en)
Spanish (es)
Inventor
Douglas J Demarini
Henriquez Francisco
Wang Lihong
Ngocdiep T Le
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of UY33818A publication Critical patent/UY33818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001033818A 2010-12-20 2011-12-19 Nueva composicion farmaceutica UY33818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
UY33818A true UY33818A (es) 2012-07-31

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033818A UY33818A (es) 2010-12-20 2011-12-19 Nueva composicion farmaceutica

Country Status (38)

Country Link
US (5) US8580304B2 (cg-RX-API-DMAC10.html)
EP (4) EP4159204B1 (cg-RX-API-DMAC10.html)
JP (2) JP6126014B2 (cg-RX-API-DMAC10.html)
KR (1) KR101911109B1 (cg-RX-API-DMAC10.html)
CN (1) CN103998041B (cg-RX-API-DMAC10.html)
AR (2) AR084102A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011349422B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013015602B1 (cg-RX-API-DMAC10.html)
CA (1) CA2822701C (cg-RX-API-DMAC10.html)
CL (1) CL2013001779A1 (cg-RX-API-DMAC10.html)
CR (1) CR20130352A (cg-RX-API-DMAC10.html)
CY (1) CY1123376T1 (cg-RX-API-DMAC10.html)
DK (3) DK4159204T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2013000138A (cg-RX-API-DMAC10.html)
EA (1) EA025198B1 (cg-RX-API-DMAC10.html)
ES (3) ES2820536T3 (cg-RX-API-DMAC10.html)
FI (2) FI4159204T3 (cg-RX-API-DMAC10.html)
HR (3) HRP20240564T1 (cg-RX-API-DMAC10.html)
HU (3) HUE066526T2 (cg-RX-API-DMAC10.html)
IL (1) IL226855A (cg-RX-API-DMAC10.html)
JO (1) JO3594B1 (cg-RX-API-DMAC10.html)
LT (3) LT4159204T (cg-RX-API-DMAC10.html)
MA (1) MA34883B1 (cg-RX-API-DMAC10.html)
MX (1) MX2013007073A (cg-RX-API-DMAC10.html)
MY (1) MY170501A (cg-RX-API-DMAC10.html)
NZ (1) NZ612157A (cg-RX-API-DMAC10.html)
PE (1) PE20140040A1 (cg-RX-API-DMAC10.html)
PH (1) PH12013501209A1 (cg-RX-API-DMAC10.html)
PL (3) PL4159204T3 (cg-RX-API-DMAC10.html)
PT (3) PT4159204T (cg-RX-API-DMAC10.html)
RS (2) RS65497B1 (cg-RX-API-DMAC10.html)
SG (1) SG191054A1 (cg-RX-API-DMAC10.html)
SI (3) SI2654736T1 (cg-RX-API-DMAC10.html)
TW (1) TWI505828B (cg-RX-API-DMAC10.html)
UA (1) UA113158C2 (cg-RX-API-DMAC10.html)
UY (1) UY33818A (cg-RX-API-DMAC10.html)
WO (1) WO2012088033A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201304189B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
PE20151024A1 (es) * 2012-11-30 2015-07-27 Glaxosmithkline Llc Composicion farmaceutica novedosa
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
CN109789141B (zh) * 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
CA3041561A1 (en) * 2016-11-25 2018-05-31 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110031370A (ko) 2008-07-08 2011-03-25 베타 파마, 인크. 염산 icotinib, 합성, 결정형, 약학적 조성물 및 이의 사용
BR112012006693A2 (pt) 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
BR112012006485A2 (pt) 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
WO2011038380A2 (en) * 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
CN104382906A (zh) 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
JP5903433B2 (ja) * 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なvegfr阻害剤およびmek阻害剤の医薬的組み合わせ
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
RS65497B1 (sr) 2024-06-28
HRP20240564T1 (hr) 2024-09-27
EP4159204B1 (en) 2024-02-14
CN103998041B (zh) 2016-08-17
CA2822701C (en) 2018-10-23
US9399021B2 (en) 2016-07-26
PL2654736T3 (pl) 2020-12-14
US20120183613A1 (en) 2012-07-19
TW201249441A (en) 2012-12-16
EA201390913A1 (ru) 2014-04-30
US20140154316A1 (en) 2014-06-05
ES2985024T3 (es) 2024-11-04
CY1123376T1 (el) 2021-12-31
PL4159205T3 (pl) 2024-06-24
LT4159205T (lt) 2024-05-10
EP2654736A2 (en) 2013-10-30
SI2654736T1 (sl) 2020-10-30
EP4159204A1 (en) 2023-04-05
US9271941B2 (en) 2016-03-01
LT4159204T (lt) 2024-05-10
EP2654736A4 (en) 2015-04-22
HRP20240563T1 (hr) 2024-08-16
CL2013001779A1 (es) 2014-06-27
WO2012088033A3 (en) 2014-03-13
US20140099365A1 (en) 2014-04-10
PT4159204T (pt) 2024-05-07
DOP2013000138A (es) 2013-11-30
AR122185A2 (es) 2022-08-24
MA34883B1 (fr) 2014-02-01
RS65496B1 (sr) 2024-06-28
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
BR112013015602A2 (pt) 2017-02-21
CR20130352A (es) 2013-12-18
US9155706B2 (en) 2015-10-13
KR101911109B1 (ko) 2018-10-23
TWI505828B (zh) 2015-11-01
DK4159205T3 (da) 2024-05-13
PT4159205T (pt) 2024-05-08
AU2011349422B2 (en) 2015-12-10
PE20140040A1 (es) 2014-02-26
US20140037726A1 (en) 2014-02-06
PH12013501209A1 (en) 2013-07-29
CA2822701A1 (en) 2012-06-28
EP4159205A1 (en) 2023-04-05
HUE050788T2 (hu) 2021-01-28
ES2820536T3 (es) 2021-04-21
FI4159204T3 (fi) 2024-04-22
IL226855A (en) 2017-04-30
EA025198B1 (ru) 2016-11-30
MX2013007073A (es) 2013-09-26
UA113158C2 (xx) 2016-12-26
PT2654736T (pt) 2020-09-24
SI4159205T1 (sl) 2024-06-28
US8580304B2 (en) 2013-11-12
PL4159204T3 (pl) 2024-07-01
WO2012088033A2 (en) 2012-06-28
US20130266649A1 (en) 2013-10-10
AU2011349422A1 (en) 2013-05-02
KR20130130028A (ko) 2013-11-29
JO3594B1 (ar) 2020-07-05
HUE066526T2 (hu) 2024-08-28
SI4159204T1 (sl) 2024-06-28
FI4159205T3 (fi) 2024-04-23
ES2982775T3 (es) 2024-10-17
SG191054A1 (en) 2013-08-30
DK2654736T3 (da) 2020-09-14
JP2014510704A (ja) 2014-05-01
ZA201304189B (en) 2014-02-26
MY170501A (en) 2019-08-08
NZ612157A (en) 2015-05-29
JP2017137299A (ja) 2017-08-10
EP3808343A1 (en) 2021-04-21
AR084102A1 (es) 2013-04-24
LT2654736T (lt) 2020-09-25
EP4159205B1 (en) 2024-02-14
BR112013015602B1 (pt) 2022-03-03
JP6126014B2 (ja) 2017-05-10
CN103998041A (zh) 2014-08-20
HRP20201409T1 (hr) 2020-11-27
HUE066525T2 (hu) 2024-08-28

Similar Documents

Publication Publication Date Title
DOP2013000138A (es) Nueva composición farmacéutica
UY35157A (es) Nueva composición farmacéutica conteniendo dimetilsulfóxido
CL2020000031A1 (es) Aparatos y métodos de cribas moldeadas por inyección. (divisional solicitud 201801786).
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
CL2014000821A1 (es) Compuestos derivados de 1h-pirazolo[4,3-c]quinolin-4(5h)-ona, inhibidores de la fosfodiestera 9 (pde9); composicion farmaceutica que los comprende; y agente para mejorar la alteracion cognitiva en la enfermedad de alzheimer.
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
BR112014001050A2 (pt) copolímero em bloco de poliéster poliamida, método para a preparação do mesmo, composição, produtos de liberação controlada e de cuidado pessoal, e, método para preparação de uma composição de gel
NI201200072A (es) Métodos y composiciones para tratar cáncer
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MY191875A (en) Solid dosage form
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
BR112013013930A2 (pt) método para criar um produto de sementes misturadas de alta precisão, método para fazer a separação entre dois ou mais grupos de sementes e um produto de mistura de sementes
GT201500069A (es) Piridinonas bicìclicas novedosas
UY30308A1 (es) Moduladores de mglur5 v
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
AR093939A1 (es) Composiciones que comprenden vortioxetina y donepezil
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia
UY34031A (es) Componente de éster aromático en la formulación de composiciones agroquímicas
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
CO6781490A2 (es) Nueva composición farmacéutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211104

110 Patent granted

Effective date: 20221019